New trends in pulmonary hypertension

Area of Science:

• Cardiology
• Pulmonology
• Vascular Medicine

Background:

• Pulmonary hypertension (PH) is a significant vascular disease associated with high morbidity and mortality.
• Recent advancements have focused on improving the recognition, diagnosis, and management of PH.
• The European Society of Cardiology/European Respiratory Society (ESC/ERS) released revised guidelines in 2022.

Purpose of the Study:

• To highlight new trends in the diagnosis and management of PH.
• To focus on the key updates from the 2022 ESC/ERS guidelines.
• To discuss advancements in risk stratification, treatment pathways, and patient-centered care for PH.

Main Methods:

• Review and synthesis of the latest European Society of Cardiology/European Respiratory Society guidelines for PH.
• Analysis of revised hemodynamic definitions and the introduction of exercise PH definitions.
• Examination of updated risk stratification strategies, emphasizing comorbidities and phenotyping.

Main Results:

• Revised hemodynamic definition of PH and a new definition for exercise PH.
• Refined risk stratification methods, incorporating comorbidities and phenotyping.
• Emerging treatment options, including a fourth pathway for pulmonary arterial hypertension and targeted therapies for group 3 PH.
• Increased emphasis on supervised training and potential interventional therapies for stable PH.

Conclusions:

• The landscape of PH management is evolving with significant progress and innovation.
• Revised guidelines provide a framework for earlier disease identification and enhanced patient-centered, goal-oriented treatment.
• New therapeutic strategies offer promising future directions for managing various forms of PH.